Careers

Diversity

With 17 offices, from New York to Los Angeles and Seattle to Orlando, we live and work in communities all over the U.S., collaborating across locations, disciplines and even borders. Our experienced, highly ranked lawyers serve businesses wherever they are and wherever they want to go.

Offices

About Us

Pages

Professionals

Thought leadership: blogs, podcasts, videos, publications, events and news

Insights

Services

Pro Bono

Am Law 100 firm with practices in Business, Digital Assets and Data Management, Intellectual Property, Labor & Employment, Litigation and Tax.

Home | BakerHostetler

2024 BHIPP - BakerHostetler IP Perspective

Are Your Granted Patents in Danger of a Post-Grant Double Patenting Challenge?

IP Intelligence Report

World IP Day – Celebrating Innovation and Creativity to Build Our Common Future

Employment Law Spotlight

The Birth of Another Form of Paid Leave: Prenatal Leave for New York-Based Employees

BREAKING NEWS: DOL Unveils Final OT Rule, Significantly Raising Salary Thresholds for Exemptions

Partner Carl Hittinger was quoted in an April 4, 2023, article in the Daily Journal titled “FTC Blocks Illumina’s purchase of cancer biotech.” The piece focused on the Federal Trade Commission’s opposition to the purchase of Grail, Inc. by the San Diego biotechnology company Illumina Inc.  Hittinger told the publication that it is premature to draw too many conclusions from the decision because there have been so few cases challenging vertical mergers.  <a href="https://www.dailyjournal.com/articles/371959" target="_blank" rel="noopener">Read the article (subscription required).</a>

Carl Hittinger Comments on FTC’s Effort to Block Purchase of Biotech Firm

Featured Insights

Related Services

Featured Insights